Inclusion Criteria:

- They have non-resectable stage III or IV metastatic melanoma with measurable disease
and have agreed to be treated with biochemotherapy.

- They have Zubrod performance status of 0-1

- They have normal blood counts with a white blood count (WBC) count >/= 3,500/mm^3,
ANC >/= 1,500/mm^3 and a platelet count >/= 100,000/mm^3 and have serum creatinine
<1.5 mg/dl, and serum bilirubin level < 1.5 mg/dl, and no evidence of significant
cardiac or pulmonary dysfunction.

- They have no significant intercurrent illness such as a serious infection,
significant psychiatric illness, hypercalcemia (calcium >11 mg), gastro-intestinal
(GI) bleeding or evidence of brain metastasis.

- They have not been exposed to prior interferon, interleukin-2 or previous
chemotherapy including regional perfusion. Prior radiation therapy for metastatic
melanoma is permitted provided the patient has unirradiated metastatic sites for
response evaluation and has fully recovered from its toxicity.

- They must have been off corticosteroids for at least 2 weeks.

Exclusion Criteria:

- They are younger than 18 years or more than 65 years of age and those with an
expected survival of less than 8 weeks or a Zubrod performance status of 2, 3 or 4.

- They have received previous treatment with any prior systemic chemotherapy for
unresectable metastasis including and not limited to the following drugs: cisplatin,
vinblastine, Dacarbazine (DTIC), interferon and interleukin-2

- They have active central nervous system involvement by melanoma either as brain
metastasis, spinal cord compression, or meningeal carcinomatosis".

- They have significant cardiac illness such as symptomatic coronary artery disease or
previous history of myocardial infarction, impaired left ventricular function or
serious cardiac arrhythmias requiring therapy.

- They have significant impairment of pulmonary function on account of chronic
bronchitis or chronic obstructive pulmonary disease (COPD).

- They have symptomatic effusions on account of pleural, pericardial or peritoneal
metastasis of melanoma.

- They have history of a second malignant tumor (except for other skin cancers and in
situ carcinoma of the cervix) within the past 5 years and uncertainty about the
histologic nature of the metastatic lesions.

- They are on corticosteroids or any other type of immunosuppressive agent (e.g.,
methotrexate, chloroquine, azathioprine, cyclophosphamide).

- They are pregnant or breast feeding. Patients of childbearing potential must agree to
use an effective method of contraception.

- They have known hypersensitivity to any of the study drugs or to other selective
5-HT3(subscript).

- They have ongoing emesis due to any organic etiology including but not limited to
central nervous system or gastrointestinal metastasis.

- They have grade 2 or higher nausea due to administration of drugs including but not
limited to narcotics.